[1] Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003, 348:1546–54. [2] Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis, 2002, 34: 909–917. [3] Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis, 2006, 43:577–84. [4] Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol, 2004, 42:4419–31. [5] Baddley JW, Pappas PG, Smith AC, et al. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol, 2003, 41: 5525–5529. [6] Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis, 2004, 38:1237–42. [7] Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect, 2004, 10(Suppl 1):48–66. [8] Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol, 2003, 41:3623–6. [9] Kelaher A. Two non-invasive diagnostic tools for invasive as pergilosis: (1-3)-beta-Dglucan and the galactomannan assay. Clin Lab Sci, 2006, 19 (4) : 222-224. [10] Mirhendi H, Makimura K, Khoramizadeh M, et al. A one-enzyme PCR-RFLP assay for identification of six medically important Candida species. Nippon Ishinkin Gakkai Zassh, 2006, 47:225–229. |